2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Thrombocytopenias, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, Research, APL, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Pregnant, Animal Model
PAPER

1296 Postpartum hemorrhage, mode of delivery, and blood transfusion outcomes in pregnant women with von Willebrand disease: A retrospective cohort study

An To, MD, MS, Natalie Almond, MD2, Sasha Lake, MD3, Peace Nnaji4, Olatomiwa I Ajayi5, Chiamaka Nwachukwu, MBBS6, Nicoy Downie, MD7, Olusegun Bakare, MBBS8, Maissaa Janbain, MD9
1 Tulane University School of Medicine, New Orleans, Louisiana, United States
2 Tulane University School of Medicine, New Orleans, Louisiana, United States
3 Tulane University School of Medicine, New Orleans, Louisiana, United States
4 LSU Health Sciences Center - New Orleans, New Orleans, United States
5 Tulane University School of Medicine, New Orleans, Louisiana, United States
6 Tulane University School of Medicine, New Orleans, Louisiana, United States
7 Massachusetts General Hospital/Brigham and Women’s Hospital, Boston, Massachusetts, United States
8 Tulane University School of Medicine, New Orleans, Louisiana, United States
9 Tulane University School of Medicine, New Orleans, Louisiana, United States

Background Von Willebrand disease (VWD) is the most common inherited bleeding disorder and is associated with an increased risk of postpartum hemorrhage (PPH) (Brignardello-Petersen, Romina et al. Blood Advances 2022).  Although von Willebrand factor (VWF) levels physiologically increase during pregnancy, this rise may not reach the levels observed in pregnant women without VWD, predisposing individuals with VWD to PPH (Brignardello-Petersen, Romina et al. Blood Advances 2022). Real-world data describing delivery outcomes across VWD subtypes remain limited, particularly outside of specialized hemophilia treatment centers (HTCs).

Methods This retrospective study reviewed delivery records of women with a diagnosis of VWD who delivered at, or were co-managed by the Louisiana Center for Bleeding and Clotting Disorders between 2008 and 2023. Patients were identified through electronic medical records (EMR). For analysis, VWD subtype was categorized into two groups: Type 1 versus Non-Type 1 (including type 2A, 2B, 2M,  and undocumented/unknown subtypes) given small individual sample sizes. Outcomes of interest were PPH, mode of delivery (cesarean vs. vaginal), and blood transfusion requirements. Data were analyzed in SPSS using Fisher's exact test.

Results This study included 76 unique deliveries from 37 women with VWD (Type 1: 39 deliveries and Non-Type 1: 37 deliveries). Cesarean deliveries occurred in 32.9% (25/76), PPH in 30.3% (23/76), and blood transfusion in 6.7% (5/75).

Mode of delivery differed significantly between groups: women with Non-Type 1 VWD had a higher cesarean rate (54.1%, 20/37) than women with Type 1 VWD (12.8%, 5/39, Fisher's exact p < 0.001). PPH was numerically more common in the Non-Type 1 group (37.8%, 14/37) than in Type 1 (23.1%, 9/39), but this difference was not statistically significant (Fisher's exact p = 0.213). Blood transfusion was also more frequent in Non-Type 1 women (10.8%, 4/37) compared with Type 1 (2.6%, 1/38), although this difference was not statistically significant (Fisher's exact p = 0.200) and was based on only five transfusion events overall.

Conclusion Women with Non-Type 1 VWD had significantly higher rates of cesarean delivery compared with women with Type 1 VWD. The reasons for cesarean delivery were not available in this study. Non-Type 1 VWD was associated with higher rates of PPH and blood transfusion, although these differences did not reach statistical significance. This trend is consistent with decreased VWF activity in Type 2 VWD, despite the physiologic increase in factor VIII and VWF antigen levels during pregnancy (Abdul-Kadir, R., & Ragni, M. V., Haematologica 2026). The lack of statistical significance for PPH and blood transfusion outcomes may reflect limited statistical power rather than the absence of an association, given the observed differences between groups (23.1% vs. 37.8% for PPH; 2.6% vs. 10.8% for blood transfusion) and the small overall number of transfusion events.

Limitations This study is limited by its single-center design and modest sample size, which reduced statistical power to detect true differences between groups. Additionally, combining type 2A, 2B, 2M, and unknown subtypes into a single "Non-Type 1" category may obscure clinically meaningful differences among individual VWD subtypes. A substantial proportion of records (20%) had unknown VWD subtype classification, which may also represent a potential source of confounding. Future analysis will evaluate obstetric indications for cesarean delivery, compare outcomes between patients managed solely by obstetric providers versus those co-managed by HTCs, and examine treatment-specific outcomes.

An To, MD, MS: No relevant conflicts of interest to declare.